Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-02, Stock:LLY, The news for the past five days is as follows:
2018-03-23: NEWS1: Radius Health Down on Negative CHMP Opinion for Lead Drug.NEWS2: Radius Health Down on Negative CHMP Opinion for Lead Drug.NEWS3: Incyte’s Product Portfolio in March 2018.NEWS4: Incyte’s Revenue Stream in 4Q17.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS6: Incyte’s Revenue Trends in 4Q17.
2018-03-26: NEWS1: Roche's Tecentriq Combo Study Meets Co-Primary Endpoint.NEWS2: Roche's Tecentriq Combo Study Meets Co-Primary Endpoint.NEWS3: Top Analyst Reports for Nike, Eli Lilly & NVIDIA.NEWS4: Top Analyst Reports for Nike, Eli Lilly & NVIDIA.NEWS5: Top Analyst Reports for Nike, Eli Lilly & NVIDIA.NEWS6: Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today.NEWS7: Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today.NEWS8: Here&apos;s Why Biohaven Pharmaceutical Holding Co Ltd&apos;s Getting Hammered Today.NEWS9: Pfizer's Chantix Fails in Phase IV Study in Young Smokers.NEWS10: Pfizer's Chantix Fails in Phase IV Study in Young Smokers.NEWS11: Analysts’ Recommendations for Incyte in March 2018.NEWS12: Pfizer&apos;s Chantix Fails in Phase IV Study in Young Smokers.NEWS13: Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?.NEWS14: Incyte’s Collaborations and Developments in 2018.NEWS15: See what the IHS Markit Score report has to say about Eli Lilly And Co..
2018-03-27: NEWS1: The Zacks Analyst Blog Highlights: Nike, Eli Lilly, NVIDIA, L Brands and Alleghany.
2018-03-28: NEWS1: How Bristol-Myers Squibb’s Oncology Drugs Performed in 4Q17.NEWS2: How Bristol-Myers Squibb’s Oncology Drugs Performed in 4Q17.NEWS3: A Look at Bristol-Myers Squibb’s 4Q17 Revenue.NEWS4: A Look at Bristol-Myers Squibb’s 4Q17 Revenue.NEWS5: How Novartis’s Oncology Segment Drugs Are Performing.NEWS6: Bristol-Myers Squibb’s Valuation in March 2018.NEWS7: FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy.NEWS8: FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy.NEWS9: 3 Biotechs That Could Get Big Boosts in April.NEWS10: 3 Biotechs That Could Get Big Boosts in April.NEWS11: 3 Biotechs That Could Get Big Boosts in April.NEWS12: Biotech Stocks Facing FDA Decision In April.NEWS13: Biotech Stocks Facing FDA Decision In April.
2018-03-29: NEWS1: What’s behind Omeros’s Cash Flow.NEWS2: What’s behind Omeros’s Cash Flow.NEWS3: Analysts’ Ratings for Omeros and Peers in March 2018.NEWS4: Analysts’ Ratings for Omeros and Peers in March 2018.NEWS5: Eli Lilly’s Segment-by-Segment Performance in 4Q17.NEWS6: Eli Lilly’s Segment-by-Segment Performance in 4Q17.NEWS7: Eli Lilly’s Revenue in 4Q17.NEWS8: Eli Lilly’s Revenue in 4Q17.NEWS9: Eli Lilly and Company’s Valuation in March 2018.NEWS10: Eli Lilly and Company’s Valuation in March 2018.

Answer: Decrease